ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

In Brief: Kennedy’s Oversight Hearings Will Include Cancer Program, Important To Act Renewal

January 26, 1979

ACCC T Discuss Personnel, Fund Sources, Clinical Research At Annual Meeting

January 9, 1976

Charles Balch resigns as ASCO executive vice president; Joseph Bailes named interim EVP.

October 28, 2005

How Elite Institutions Were Affected By A Decade of Constricted Funding

October 31, 2014

Radiation Doesn’t Add Benefit For Early Endometrial Cancer

June 29, 2007

Peer Review Study Team Plans Hearing

December 12, 1975